Abstracts tagged "Comorbidity"

Abstract Number: 325 • 2018 ACR/ARHP Annual Meeting
A Comparison of RADAI5 and RAPID3 Disease Measures
Ryan Jessee, Amanda M. Eudy and Megan E. B. Clowse, Department of Medicine, Division of Rheumatology and Immunology, Duke University, Durham, NC
Background/Purpose: Treat to target has been shown to improve outcomes in multiple rheumatology diseases although relies on accurate disease measures. Our academic clinic routinely measures…
Abstract Number: 2719 • 2018 ACR/ARHP Annual Meeting
Tracking the Risk of Infections in ANCA-Associated Vasculitis: Results from a Scottish Matched-Cohort Study
Shifa Sarica¹, Neeraj Dhaun², Jan Sznajd³, John Harvie³, Nicola Joss³, John McLaren⁴, Lucy McGeoch⁵, Nicole Amft⁶, Vinod Kumar⁷, Angharad Marks¹, Corri Black¹ and Neil Basu¹, ¹Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, United Kingdom, ²University/British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom, ³Department of Rheumatology, Raigmore Hospital, Inverness, United Kingdom, ⁴Fife Rheumatic Diseases Unit, Whyteman's Brae Hospital, Kirkcaldy, United Kingdom, ⁵Center for Rheumatic Diseases, Glasgow Royal Infirmary, Glasgow, United Kingdom, ⁶Department of Rheumatology, Western General Hospital, Edinburgh, United Kingdom, ⁷Rheumatology Department, Ninewells Hospital, Dundee, United Kingdom
Background/Purpose: Evaluation of infection risk in ANCA-associated vasculitis (AAV) has been limited to small, selected populations and/or serious episodes. In this large study, we aimed…
Abstract Number: 332 • 2018 ACR/ARHP Annual Meeting
Components of Impaired Physical Function and Disability in a Non-Rheumatic Population. Normative Values of the Health Assessment Questionnaire Disability Index
C Alejandro Arce-Salinas¹, H FABRICIO ESPINOSA-ORTEGA² and Olivia Enriquez-Antonio³, ¹INTERNAL MEDICINE, Hospital Central Sur PEMEX, MEXICO, Mexico, ²Rheumatology Department, Karolinska Universitetssjukhuset, Stockolm, Sweden, ³Internal Medicine, Hospital Central Sur PEMEX, mexico, Mexico
Background/Purpose: HAQ-Di is broadly used to measure disability in RA, its assessment might influence taking decision process. However, it cannot differentiate disability related to arthritis,…
Abstract Number: 2768 • 2018 ACR/ARHP Annual Meeting
Comorbidity Accrual and Mortality in an Inception Cohort of Patients with Giant Cell Arteritis and Polymyalgia Rheumatica: A Single-Center, Observational Long-Term Study
Elisheva Pokroy-Shapira¹, Ariela Dortort-Lazar^2,3 and Yair Molad^4,5, ¹Rheumatology Unit, Rabin Medical Center, Beilinson Hospital and Sackler Faculty of Medicine, Tel Aviv University, Petach Tikva, Israel, ²Rheumatology Unit, Beilinson hospital Rabin Medical Center, Petah Tikva, Israel, ³Sackler Faculty of Medicine Tel Aviv university, Tel Aviv, Israel, ⁴Rheumatology Unit, Rabin Medical Center, Beilinson Hospital, Petach Tikva, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁵Rheumatology Unit, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel
Background/Purpose: Patients with giant-cell arteritis (GCA) and polymyalgia rheumatica (PMR) are treated with high cumulative glucocorticoid (GC) dose during their disease course. We sought to…
Abstract Number: 507 • 2018 ACR/ARHP Annual Meeting
Echocardiographic Markers of Right Ventricle Dysfunction in Hispanic Patients with Rheumatoid Arthritis: A Case-Control Study
José R. Azpiri-López¹, Dionicio A. Galarza-Delgado², Iris J. Colunga-Pedraza³, Jose A. Davila-Jimenez⁴, Estefania E. Abundis-Marquez⁴, Andres H. Guillen-Lozoya⁴, Francisco J. Torres-Quintanilla⁴, Aldo Valdovinos-Bañuelos⁴, Ray Ramos-Cázares⁴, Raymundo Vera-Pineda⁴, Jesus A. Cardenas-de la Garza⁴, Rosa I. Arvizu-Rivera⁴ and Adrián Martínez-Moreno⁴, ¹Cardiology, Hospital Universitario, UANL, Monterrey, Mexico, ²Chief of Rheumatology, Hospital Universitario, UANL, Monterrey, Mexico, ³Rheumatology, Hospital Universitario, UANL, Monterrey, Mexico, ⁴Hospital Universitario, UANL, Monterrey, Mexico
Background/Purpose: Screening for cardiovascular (CV) disease in patients with rheumatoid arthritis (RA) remains controversial, however, there is agreement in considering echocardiography as the most immediate…
Abstract Number: 2778 • 2018 ACR/ARHP Annual Meeting
High Prevalence of Vascular Surgery and Autoimmune Comorbidity in Takayasu Arteritis
Tsuyoshi Shirai¹, Tomoyuki Muto², Yuko Shirota¹, Hiroshi Fujii¹, Tomonori Ishii³ and Hideo Harigae¹, ¹Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan, ²Tohoku University Graduate School of Medicine, Sendai, Japan, ³Clinical Research, Innovation and Education Center, Tohoku University Hospital, Sendai, Japan
Background/Purpose: Large vessel vasculitis (LVV) is the arteritis in aorta and its major branches, and classified into Takayasu arteritis (TAK) and giant cell arteritis (GCA).…
Abstract Number: 508 • 2018 ACR/ARHP Annual Meeting
Non-Invasive Evaluation of Left Atrial Pressure in Hispanic Patients with Rheumatoid Arthritis: A Case-Control Study
José R. Azpiri-López¹, Dionicio A. Galarza-Delgado², Iris J. Colunga-Pedraza³, Jose A. Davila-Jimenez⁴, Estefania E. Abundis-Marquez⁴, Andres H. Guillen-Lozoya⁴, Francisco J. Torres-Quintanilla⁴, Aldo Valdovinos-Bañuelos⁴, Ray Ramos-Cázares⁴, Raymundo Vera-Pineda⁴, Jesus A. Cardenas-de la Garza⁴, Rosa I. Arvizu-Rivera⁴ and Adrián Martínez-Moreno⁴, ¹Cardiology, Hospital Universitario, UANL, Monterrey, Mexico, ²Chief of Rheumatology, Hospital Universitario, UANL, Monterrey, Mexico, ³Rheumatology, Hospital Universitario, UANL, Monterrey, Mexico, ⁴Hospital Universitario, UANL, Monterrey, Mexico
Background/Purpose: In the last several years a higher prevalence of heart failure has been described in Rheumatoid arthritis (RA) patients, particularly heart failure with preserved…
Abstract Number: 512 • 2018 ACR/ARHP Annual Meeting
Incidence of First Cardiovascular Event in Spanish Patients with Chronic Inflammatory Rheumatic Diseases: Prospective Data from an Observational Multicentric Study
Maria Auxiliadora Martin¹, Santos Castañeda², Carlos González-Juanatey³, Fernando Sánchez-Alonso⁴, María Carmen García-Gómez⁵, R López-González⁶, Jesus Babio⁷, Antonio Juan-Mas⁸, María P Moreno-Gil⁹, Olga Sanchez-González¹⁰, Montserrat Romera¹¹, Jose A Pinto-Tasende¹², Jose A Piqueras¹³, Dolores Fábregas¹⁴, Javier Llorca¹⁵ and Miguel Angel González-Gay¹⁶, ¹Research Unit of Spanish Society of Rheumatology,, Madrid, Spain, ²Hospital Universitario La Princesa, IIS-Princesa, Madrid, Spain, ³Cardiology Division, Hospital Xeral-Calde, Lugo, Spain, ⁴Unidad de Investigación, Spanish Society of Rheumatology, Madrid, Spain, ⁵Rheumatology Division, Consorci Sanitari de Terrassa, Terrassa (Barcelona), Spain, ⁶Rheumatology, Complejo Hospitalario de Zamora. Spain, Zamora, Spain, ⁷Rhaumatology, H General de Cabueñes, Gijon, Spain, ⁸Division of Rheumatology, Hospital Son Llatzer, Palma de Mallorca, Spain, Spain, ⁹Division of Rheumatology, Hospital San Pedro de Alcántara, Cáceres, Spain, ¹⁰Division of Rheumatology, Hospital del Sureste, Madrid, Spain, ¹¹Division of Rheumatology, Hospital de Bellvitge, Barcelona, Spain, ¹²Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, ¹³Division of Rheumatology, Hospital Universitario de Guadalajara, Guadalajara, Spain, ¹⁴Division of Rheumatology, Hospital de Barbastro, Huesca, Spain, ¹⁵Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, Santander, Spain, ¹⁶School of Medicine, University of Cantabria, Santander, Spain, Santander, Spain
Background/Purpose: To determine the incidence and risk factors implicated in the development of first cardiovascular event (CVE) in patients with chronic inflammatory rheumatic diseases (CIRD)…
Abstract Number: 645 • 2018 ACR/ARHP Annual Meeting
Real World Secukinumab Study in Ankylosing Spondylitis and Psoriatic Arthritis – Comorbidities and Extraarticular Manifestations: Incidence and Status throughout a Non-Interventional Study in Germany
Uta Kiltz¹, Peter Kaestner², Holger Krauel², Ilka Schwarze³, Jan Brandt-Juergens⁴, Monika Maier-Peuschel⁵, Carolin Legeler⁵, Justyna Veit⁵ and Hans-Peter Tony⁶, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Rheumatology, Ambulantes Rheumazentrum, Erfurt, Germany, ³Praxis internistische Rheumatologie, Leipzig, Germany, ⁴Rheumatology, Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁵Novartis Pharma GmbH, Nürnberg, Germany, ⁶Rheumatology/Immunology, Medizinische Klinik II, Universitätsklinik, Würzburg, Germany
Background/Purpose: Patients with psoriatic arthritis (PsA) or ankylosing spondylitis (AS) may suffer from extraarticular (EA) manifestations (uveitis, psoriasis) and have higher rates of comorbidities like…
Abstract Number: 881 • 2018 ACR/ARHP Annual Meeting
Association of Comorbidities with DAS28 Disease Status and Remission in Race/Ethnic Groups with Rheumatoid Arthritis
Sharon Dowell¹, Rodolfo Perez-Alamino², Christopher J. Swearingen³, Gail S. Kerr⁴ and Yusuf Yazici⁵, ¹Internal Medicine, Howard University, Washington, DC, ²Rheumatology Department, Hospital de Clínicas Pte. Dr. Nicolás Avellaneda, Tucumán, Argentina, ³Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁴Rheumatology, Washington DC VAMC and Georgetown and Howard University, Washington, DC, ⁵New York University School of Medicine, New York, NY
Background/Purpose: Racial/ethnic disparities in comorbidity (CM) in rheumatoid arthritis (RA) may confound treatment and outcomes. Rheumatic Disease Comorbidity Index (RDCI) is a validated tool predicting…
Abstract Number: 1270 • 2018 ACR/ARHP Annual Meeting
Lack of Association of Comorbidities with Ultrasonographic Urate Deposition in Asymptomatic Hyperuricemia
Sharon Dowell¹, Gail S. Kerr², Alvin F. Wells³, Richard Haddad⁴, Paul DeMarco⁵, Joyce Joseph⁶, Mercedes Quinones⁷, Shelby Hochberg⁸, Jennifer Ude⁹, Jim Huang¹⁰ and David Nashel⁶, ¹Division of Rheumatology, Howard University, Washington, DC, ²Rheumatology, Washington DC VAMC and Georgetown and Howard University, Washington, DC, ³Rheumatology and Immunotherapy Center, Franklin, WI, ⁴The Hospital for Special Surgery, New York, New York, NY, ⁵Georgetown University School of Medicine, Washington, DC, ⁶Internal Medicine, Division of Rheumatology, Washington DC VA Medical Center, Washington, DC, ⁷Internal Medicine, Division of Rheumatology, Washington DC VA Medical Center and Howard University, Washington, DC, ⁸Washington DC VA Medical Center and Howard University, Washinton, DC, ⁹Washington DC VA Medical Center and Howard University, Washington, DC, ¹⁰Medstar Health Research Institute, Hyattsville, MD
Background/Purpose: Hyperuricemia is common, and along with other comorbidities (CM), is increasing in prevalence. Though often asymptomatic, it is associated with subclinical urate deposition detectable…
Abstract Number: 1514 • 2018 ACR/ARHP Annual Meeting
Impact of Comorbidity Burden and Obesity on the Effectiveness of Tocilizumab in Patients with Rheumatoid Arthritis
Dimitrios A. Pappas¹, Carol J. Etzel², Margaux Crabtree³, Jennie H. Best⁴, Steve Zlotnick⁴ and Joel Kremer⁵, ¹Columbia University, New York, NY, ²Corrona LLC, Waltham, MA, ³Corrona, LLC, Waltham, MA, ⁴Genentech, Inc., South San Francisco, CA, ⁵Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Few real-world studies have evaluated the impact of comorbidity burden or obesity on the effectiveness of tocilizumab (TCZ) for the improvement of rheumatoid arthritis…
Abstract Number: 528 • 2017 ACR/ARHP Annual Meeting
Impact of Comorbidities on the Occurrence of Infections in Rheumatoid Arthritis Treated By Biologic Agents
Christopher Banse¹, Nicolas Chrin², Pascal Rottenberg³, Sophie Pouplin⁴, thierry Lequerre⁵ and Olivier Vittecoq³, ¹Rheumatology, Rouen University Hospital, Rouen, France, ²Department of Biostatistics, Rouen University Hospital, 76031 Rouen, France, ROUEN, France, ³INSERM U905 & Normandy University, Institute for Research and Innovation in Biomedicine, Rouen, France, ⁴Rheumatology Department & Inserm 905, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, ⁵Rheumatology Department, Rouen University Hospital, University of Rouen, 76031 Rouen, France., ROUEN, France
Background/Purpose: to investigate the potential relationship between the number of comorbidities at initiation of biotherapy and the occurrence of a severe infection or recurrent infections…
Abstract Number: 1004 • 2017 ACR/ARHP Annual Meeting
Arthritis Impact at the State and County Level — United States, 2015
Kamil E. Barbour¹, Suson Moss², Janet Croft², Jennifer M. Hootman³, Louise Murphy⁴, Kristina Theis², Yan Wang², Hua Lu², Teresa J. Brady¹ and Charles G. Helmick², ¹Arthritis Program, Centers for Disease Control and Prevention, Atlanta, GA, ²Centers for Disease Control and Prevention, Atlanta, GA, ³Centers for Disease Control and Prevention, Kennesaw, GA, ⁴Division of Population Health, Centers for Disease Control and Prevention, Atlanta, GA
Background/Purpose: Arthritis, a leading cause of disability, affects 54.4 million US adults. By knowing the state and county level arthritis impact, state-level public health professionals…
Abstract Number: 1036 • 2017 ACR/ARHP Annual Meeting
Blood Glucose Changes Surrounding Initiation of Tumor-Necrosis Factor Inhibitors and Conventional Disease-Modifying Anti-Rheumatic Drugs in Veterans with Rheumatoid Arthritis
Patrick R. Wood¹, Evan Manning², Joshua Baker³, Grant Cannon⁴, Lisa Davis⁵, Bryant R. England⁶, Ted R. Mikuls⁷ and Liron Caplan⁸, ¹Rheumatology, University of Colorado School of Medicine, Aurora, CO, ²University of Colorado School of Medicine, Aurora, CO, ³Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁴Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁵Div of Rheumatology, Denver Health, Denver, CO, ⁶Division of Rheumatology & Immunology, Department of Internal Medicine, Nebraska-Western IA VA Health Care System & University of Nebraska Medical Center, Omaha, NE, ⁷Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁸Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: There is evidence linking activation of the innate immune system and insulin resistance. Perturbations in glucose homeostasis upon initiation of tumor-necrosis factor inhibitors (TNFis)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].